Fused Furans for Hepatitis C NS5B Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hepatitis C virus (HCV) infection, particularly those involving HCV NS5B inhibitors like HCV-796, face challenges such as hepatic toxicity and limited sustained reduction in viral load, highlighting the need for more effective and safer therapeutic options.
Innovation Solution
Development of novel compounds of formula I and II, which are effective against HCV NS5B, offering improved mechanisms of action, binding affinity, target selectivity, solubility, safety profiles, and bioavailability, potentially used in combination with existing therapies like interferon and ribavirin.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If HCV NS5B inhibitors like HCV-796 are used as single agent therapy, then viral RNA levels decrease transiently, but the reduction is not sustained and hepatic toxicity occurs
Solution Approach 1:
The patent combines HCV NS5B inhibitor compounds with standard of care therapies (pegylated alpha-interferon and ribavirin) into a triple combination regimen. This merging of multiple therapeutic agents addresses the limitation of single-agent therapy by achieving sustained viral load reduction while maintaining safety, as demonstrated in clinical studies where the combination approach overcame the transient effect and hepatic toxicity issues of monotherapy
2Productivity
If HCV NS5B inhibitors like HCV-796 are used in combination with standard of care, then robust viral load reduction is achieved, but hepatic toxicity is observed
Solution Approach 1:
The patent modifies the chemical parameters of existing HCV NS5B inhibitor compounds to create novel derivatives with improved safety profiles. By changing molecular structure parameters (such as substituent groups on the core heterocyclic framework), the invention achieves robust viral load reduction while reducing hepatic toxicity compared to HCV-796, as evidenced by better safety data in clinical trials
3Reliability
If current standard of care (pegylated alpha-interferon and ribavirin) is used, then some sustained efficacy is achieved, but a substantial fraction of patients do not have sustained reduction in viral load
Solution Approach 1:
The patent introduces HCV NS5B inhibitor compounds as intermediary agents that enhance the mechanism of action of standard of care therapies. These compounds directly inhibit the viral polymerase enzyme, complementing the immunomodulatory effects of interferon and the antiviral effects of ribavirin, thereby achieving sustained viral load reduction in a broader patient population including those who respond suboptimally to standard therapy alone
Data Source
AI summary
The disclosure provides compounds of formula I or II, including their salts, as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV.